EGFR and colorectal carcinoma: Both FOXQ1 and THBS2 have promotional effects on CRC cell progression partly by modulating the Wnt/β-catenin and the HB-EGF/EGFR signaling pathways, thus targeting these molecules may have inhibitory effect on CRC (10, 12, 20).